Molecular Partners AG (MOLN) stock

MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 1/30

$3.09+0.00 (0.00%)

Close on Nov 11, 2026Market cap $124.76MP/E –Yield –

Molecular Partners operating margin

Operating margin is operating income as a percentage of revenue.

For fiscal 2024 it was -1231.7%, against -868.3% the year before. The highest annual figure on record is 61.5% in fiscal 2022.

Period	Period end	Value	Change (pts)
FY2024	Dec 31, 2024	-1231.7%	−363.5
FY2023	Dec 31, 2023	-868.3%	−929.8
FY2022	Dec 31, 2022	61.5%	+711.7
FY2021	Dec 31, 2021	-650.2%	−26.0
FY2020	Dec 31, 2020	-624.2%	−444.4
FY2019	Dec 31, 2019	-179.9%	–

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q2 FY2024	Jun 30, 2024	-1030.0%	–
Q2 FY2023	Jun 30, 2023	-3827.2%	–
Q2 FY2022	Jun 30, 2022	-53.5%	–

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -38.4%

Advertisement
300 × 250

See a number that looks wrong?